全文获取类型
收费全文 | 34715篇 |
免费 | 5376篇 |
国内免费 | 262篇 |
专业分类
耳鼻咽喉 | 882篇 |
儿科学 | 974篇 |
妇产科学 | 812篇 |
基础医学 | 3528篇 |
口腔科学 | 916篇 |
临床医学 | 4553篇 |
内科学 | 7486篇 |
皮肤病学 | 865篇 |
神经病学 | 3522篇 |
特种医学 | 1294篇 |
外科学 | 6274篇 |
综合类 | 621篇 |
现状与发展 | 2篇 |
一般理论 | 15篇 |
预防医学 | 3304篇 |
眼科学 | 804篇 |
药学 | 2202篇 |
1篇 | |
中国医学 | 30篇 |
肿瘤学 | 2268篇 |
出版年
2023年 | 608篇 |
2021年 | 647篇 |
2020年 | 928篇 |
2019年 | 558篇 |
2018年 | 1057篇 |
2017年 | 949篇 |
2016年 | 1086篇 |
2015年 | 1062篇 |
2014年 | 1453篇 |
2013年 | 1806篇 |
2012年 | 1446篇 |
2011年 | 1424篇 |
2010年 | 1292篇 |
2009年 | 1393篇 |
2008年 | 1311篇 |
2007年 | 1360篇 |
2006年 | 1376篇 |
2005年 | 1293篇 |
2004年 | 1114篇 |
2003年 | 1160篇 |
2002年 | 1045篇 |
2001年 | 859篇 |
2000年 | 798篇 |
1999年 | 766篇 |
1998年 | 531篇 |
1997年 | 495篇 |
1996年 | 524篇 |
1995年 | 537篇 |
1994年 | 404篇 |
1993年 | 327篇 |
1992年 | 647篇 |
1991年 | 611篇 |
1990年 | 531篇 |
1989年 | 581篇 |
1988年 | 511篇 |
1987年 | 494篇 |
1986年 | 455篇 |
1985年 | 519篇 |
1984年 | 460篇 |
1983年 | 362篇 |
1982年 | 357篇 |
1981年 | 279篇 |
1980年 | 289篇 |
1979年 | 372篇 |
1978年 | 336篇 |
1976年 | 272篇 |
1975年 | 254篇 |
1974年 | 292篇 |
1973年 | 305篇 |
1972年 | 261篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
2.
3.
4.
Rupa Narayan MD Traci M. Blonquist MS Ashkan Emadi MD PhD Robert P. Hasserjian MD Meghan Burke BS Christopher Lescinskas BS Donna S. Neuberg ScD Andrew M. Brunner MD Gabriela Hobbs MD Hanno Hock MD PhD Steven L. McAfee MD Yi-Bin Chen MD Eyal Attar MD Timothy A. Graubert MD Christina Bertoli MSN Jenna A. Moran MSN Meghan K. Bergeron MSN Julia E. Foster MSN Aura Y. Ramos BSN Tina T. Som BSN Megan K. Vartanian BSN RN Jennifer L. Story LPN Kristin McGregor MS Molly Macrae BS Tanya Behnan BS Margaret C. Wey PhD Jessica Rae BSN Frederic I. Preffer PhD Patricia Lesho BA Vu H. Duong MD Mason L. Mann BA Karen K. Ballen MD Christine Connolly BS Philip C. Amrein MD Amir T. Fathi MD 《Cancer》2020,126(6):1264-1273
5.
6.
Liam Masterson James Howard Jazmina Gonzalez-Cruz Christopher Jackson Catherine Barnett Lewis Overton Howard Liu Rahul Ladwa Fiona Simpson Margie McGrath Ben Wallwork Terry Jones Christian Ottensmeier Melvin L.K. Chua Chris Perry Rajiv Khanna Benedict Panizza Sandro Porceddu Matt Lechner 《International journal of cancer. Journal international du cancer》2020,146(8):2305-2314
Now is an exciting era of development in immunotherapy checkpoint inhibitors and their effect on the treatment of NPC. While the general prognosis of R/M disease is poor, immunotherapy offers some promise in a malignancy associated with EBV and characterized by a peritumoural immune infiltrate. Our study aims to review past and on-going clinical trials of monoclonal antibody therapies against the checkpoint inhibitors (e.g. PD1 and CTLA-4), in R/M NPC. All randomized and nonrandomized controlled trials involving immune checkpoint inhibitor interventions for treatment of NPC were included in the study. We utilized a validated “risk of bias” tool to assess study quality. Four separate Phase I–II trials report the potential of PD1 inhibitor treatment for patients with NPC. Within the observed groups, camrelizumab combined with chemotherapy achieved an objective response in 91% of patients as first-line treatment for metastatic NPC (PFS 68% at 1-year) but this was associated with a high rate of grade >3 adverse events (87%; CTCAE version 4.03). The remaining three studies focused on recurrent NPC disease in patients who had received at least one line of prior chemotherapy. Within this group, camrelizumab monotherapy achieved an objective response in 34% of patients (PFS 27% at 1-year; range across all three studies 20.5–34%). No NPC trial has yet reported on specific outcomes for non-PD1 checkpoint inhibitors but 11 on-going studies include alternative targets (e.g. PD-L1/CTLA-4) as combination or monotherapy treatments. In considering checkpoint immunotherapies for NPC, initial results show promise for anti-PD1 interventions. Further phase I–III trials are in progress to clarify clinical outcomes, fully determine safety profiles, and optimize drug combinations and administration schedules. 相似文献
7.
8.
9.